Caribou Biosciences (CRBU) Live Share Price, Invest From India

Caribou Biosciences Stock Performance

as on February 18, 2026 at 6:10 am IST

Day's Low
Day's High
$1.51
Day's Price Range
$1.58
$1.54
1.95%
Downside
2.60%
Upside
52 Week's Low
52 Week's High
$0.66
52-Week Price Range
$3.54
$1.54
57.14%
Downside
129.55%
Upside

Caribou Biosciences share price movements today

Previous Close: $1.58
Open: $1.57
Volume: 672.1K
Day's Low - High: $1.51 - $1.58
52 Week Low - High: $0.66 - $3.54

Caribou Biosciences Historical Returns

1 Month Return: + 8.22 %
3 Month Return: -16.4 %
1 Year Return: + 17.04 %
3 Year Return: -76.93 %
5 Year Return: 0 %

Caribou Biosciences Stock Fundamentals & Key Indicators

Check Caribou Biosciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$147.7M

EPS (TTM)

-1.5943

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.54

Industry PE ratio

-1.6792430278884463

PEG Ratio

EBITDA

-135.7M

Revenue (TTM)

9.3M

Profit Margin

0.00%

Return On Equity TTM

-74.28%

Caribou Biosciences Stock Valuation

Track how Caribou Biosciences P/E has moved over time to understand its valuation trends.

Caribou Biosciences in the last 5 years

Overview
Trends

Lowest (-6.17x)

September 30, 2022

Industry (-1.68x)

February 17, 2026

Today (-1.54x)

February 17, 2026

Highest (-0.55x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.54x

Caribou Biosciences vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Caribou Biosciences with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Caribou Biosciences	BUY	$147.7M	NA	-1.54	0.00%
Vertex Pharmaceuticals Incorporated	BUY	$126.0B	128.75%	32.06	32.94%
Beone Medicines Ltd	NA	$38.3B	NA	665.52	1.38%
Alnylam Pharmaceuticals, Inc.	BUY	$41.7B	100.86%	134.94	8.45%
Regeneron Pharmaceuticals, Inc.	BUY	$84.9B	66.74%	19.38	31.41%

Stock Returns calculator for Caribou Biosciences Stock including INR - Dollar returns

The Caribou Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Caribou Biosciences investment value today

Current value as on today

₹1,18,468

Returns

₹18,468

(+18.47%)

Returns from Caribou Biosciences Stock

₹14,074 (+14.07%)

Dollar Returns*

₹4,394 (+4.39%)

Analyst Recommendation on Caribou Biosciences Stock

Based on 15 analysts

BUY

86.67%

Buy

13.33%

Hold

0.00%

Sell

Based on 15 analysts, 86.67% of analysts recommend a 'BUY' rating for Caribou Biosciences. Average target price of $10.88

Caribou Biosciences Share Price Target

Get share price movements and forecasts by analysts on Caribou Biosciences.

What analysts predicted

85.85%UPSIDE

Target Price

$10.88

Current Price

$1.54

Analyzed by

15 Analysts

Target

$10.88

Caribou Biosciences target price $10.88, a slight upside of 85.85% compared to current price of $1.54. According to 15 analysts rating.

Caribou Biosciences Stock’s Investor Sentiment and Interest

Search interest for Caribou Biosciences Stock has increased by 96% in the last 30 days, reflecting an upward trend in search activity.

Time period: January 19, 2026 to February 18, 2026

Change:96% versus previous 30 day period

Caribou Biosciences Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	3	23	3	2	3	2	2	2	2	2
Gross Profit	-22	-4	1	1	2	2	-27	2	2	1
Operating Income	-32	-14	-37	-46	-43	-38	-38	-42	-47	-29
EBITDA	-32	-13	-36	-45	-42	-37	-37	-41	-34	-26
Interest Expense	-	-	3	-	-	-	-	-	-	-
Depreciation	0	1	0	0	0	1	1	1	1	0
Income Before Tax	-29	-10	-34	-41	-37	-34	-35	-39	-54	-27
Income Tax Expense	0	-3	0	0	-	-	0	-	-	-
Net Income	-29	-10	-34	-41	-37	-34	-35	-39	-54	-27
Net Profit Margin	-786.13%	-42.27%	-969.79%	-1697.57%	-1088.25%	-1713.64%	-1708.71%	-1699.58%	-2028.42%	-1253.32%

Caribou Biosciences Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	5	12	9	13	34	9
Gross Profit	5	-22	8	10	30	6
Operating Income	-34	-36	-66	-106	-116	-166
EBITDA	-30	-35	-65	-95	-112	-162
Interest Expense	0	0	0	8	-	-
Depreciation	0	0	0	1	3	3
Income Before Tax	-30	-36	-66	-99	-101	-149
Income Tax Expense	-7	-1	0	0	0	0
Net Income	-23	-34	-66	-99	-102	-149
Net Profit Margin	-404.82%	-277.55%	-697.26%	-717.79%	-296.05%	-1491.95%

Caribou Biosciences Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-10	-34	-41	-37	-34	-35	-39	-54	-27
Operating Cash Flow	-28	-21	-37	-32	-32	-35	-36	-28	-25
Investing Cash Flow	-68	-31	22	21	26	15	49	24	10
Financing Cash Flow	135	0	12	0	0	3	0	0	0
Change in Cash	37	-52	-1	-11	-5	-15	13	-4	-14

Caribou Biosciences Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-34	-66	-99	-102	-149
Operating Cash Flow	-33	-32	-90	-93	-138
Investing Cash Flow	6	-176	-93	-68	86
Financing Cash Flow	1	433	2	154	16
Change in Cash	-25	224	-182	-7	-34

Global Institutional Holdings in Caribou Biosciences

Funds	Holdings
Vanguard Group Inc	4.39%
BlackRock Inc	2.02%
Pale Fire Capital SE	0.83%
Royal Bank of Canada	0.64%
Pfizer Inc	5.04%

See all

Insights on Caribou Biosciences

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -54.09M → -27.54M (in $), with an average increase of 96.4% per quarter
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 49.9% return, outperforming this stock by 32.9%
NO EFFECT
Against Peers
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 49.1% return, outperforming this stock by 126.0%
NEGATIVE IMPACT
Price Dip
In the last 3 years, CRBU stock has moved down by -76.9%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 2.66M → 2.19M (in $), with an average decrease of 17.6% per quarter

About Caribou Biosciences

caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever" and the new york times has noted that "the pace of new discoveries and applications is dizzying." caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub

Organisation	Caribou Biosciences
Headquarters	2929 7th Street, Berkeley, CA, United States, 94710
Industry	Services
CEO	Dr. Rachel E. Haurwitz Ph.D.
E-voting on shares	Click here to vote

Key Management of Caribou Biosciences

Name	Title
Mr. Sriram Ryali M.B.A.	Chief Financial Officer
Ms. Ruhi A. Khan M.B.A.	Chief Business Officer
Mr. Ryan Fischesser	Interim Principal Accounting Officer & Controller
Ms. Amy Figueroa C.F.A.	Vice President of Investor Relations & Corporate Communications
Ms. Reigin Zawadzki	Chief People Officer
Dr. Tina Albertson M.D., Ph.D.	Chief Medical Officer
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder, CEO, President & Director
Mr. Timothy P. Kelly M.B.A.	Chief Technology Officer
Ms. Barbara G. McClung Esq., J.D.	Chief Legal Officer & Corporate Secretary
Mr. Daniel Poon	Vice President of Operations & Information Technology

FAQs

What is Caribou Biosciences share price today?

Caribou Biosciences share price today is $1.54 as on February 18, 2026 at 12:40 am IST. Caribou Biosciences share today touched a day high of $1.58 and a low of $1.51.

What is the 52 week high and 52 week low for Caribou Biosciences share?

Caribou Biosciences share touched a 52 week high of $3.54 on November 3, 2025 and a 52 week low of $0.66 on April 7, 2025. Caribou Biosciences stock price today i.e. February 18, 2026 at 12:40 am IST is trending at $1.54,which is 56.44% down from its 52 week high and 133.33% up from its 52 week low.

What is Caribou Biosciences's market capitalisation today?

Caribou Biosciences market capitalisation is $0.00T as on February 18, 2026 at 12:40 am IST.

How to invest in Caribou Biosciences Stock (CRBU) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Caribou Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Caribou Biosciences Shares that will get you 0.9740 shares as per Caribou Biosciences share price of $1.54 per share as on February 18, 2026 at 12:40 am IST.

What is the minimum amount required to buy Caribou Biosciences Stock (CRBU) from India?

Indian investors can start investing in Caribou Biosciences (CRBU) shares with as little as ₹90.652 or $1 (as of February 18, 2026 at 12:40 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹906.52 in Caribou Biosciences stock (as per the Rupee-Dollar exchange rate as on February 18, 2026 at 12:40 am IST). Based on Caribou Biosciences share’s latest price of $1.54 as on February 18, 2026 at 12:40 am IST, you will get 6.4935 shares of Caribou Biosciences. Learn more about fractional shares .